Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ocumension Therapeutics ( (HK:1477) ) has shared an announcement.
Ocumension Therapeutics announced a significant increase in revenue for the year ended December 31, 2024, with a 69.4% rise to RMB417.3 million, driven by the strong performance of its ophthalmic products and strategic cooperation with Alcon. The company also reported a narrowed adjusted net loss of RMB183.6 million, attributed to increased sales and gross profit. Key developments during the period include the approval and commercialization of new products, acceptance of biologic license applications, and the commencement of commercial production, positioning the company for future growth and stability in its product supply.
More about Ocumension Therapeutics
Ocumension Therapeutics is a company in the ophthalmology industry, focusing on the development and commercialization of eye-related pharmaceutical products. Its primary products include Youshiying, a fluocinolone intravitreal implant, and other key products like sodium hyaluronate eye drops, emedastine eye drops, and latanoprost eye drops. The company is also involved in innovative drug development with products like ZERVIATE, a cetirizine eye drop.
YTD Price Performance: 10.67%
Average Trading Volume: 2,325,112
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.09B
Learn more about 1477 stock on TipRanks’ Stock Analysis page.